- Investor's Business Daily•2 days ago
Merck and Bristol-Myers researchers aren't ready to call immuno-oncology drugs the cure for cancer, but the drugs represent a potential $25 billion market.
- TheStreet.com•2 days ago
AstraZeneca shares, meanwhile, were less-than-moved by the news.
- Market Realist•3 days ago
Amgen’s (AMGN) Prolia is currently the market leader in the underserved osteoporosis segment.
MRK : Summary for Merck & Company, Inc. Common St - Yahoo Finance
Merck & Co., Inc. (MRK)
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Day's Range||64.86 - 65.56|
|52 Week Range||49.63 - 65.87|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||32.05|
|Dividend & Yield||1.88 (2.88%)|
|1y Target Est||N/A|